Feb 21, 2023

Featuring perspectives from Dr Bob Li, including the following topics:

•      Evolution of targeted therapy for HER2-altered non-small cell lung cancer (NSCLC) (0:00)

•      Incidence and management of HER2 amplifications and mutations in NSCLC (10:45)

•      Role of ErbB/HER protein family biology in lung cancer (19:03)

•      Current and emerging roles of antibody-drug conjugates in lung cancer (33:43)

•      Considerations for clinical trial participation and improving access to care for patients with cancer (55:08)

•      Management of trastuzumab deruxtecan-associated interstitial lung disease (1:03:18)

•      Future of HER2-targeted therapy in lung cancer and beyond (1:14:39)

CME information and select publications